Can Nasal Sprays Reverse Brain Aging?—Hope from Mouse Experiments and the Expectations and Caution on Social Media

"Nasal spray that reversed brain aging." Such a headline would make many people stop in their tracks. Dementia, forgetfulness, brain fog, and decreased concentration—if a simple nasal spray could combat these inevitable signs of brain aging, it would be news that could change not only medicine but society as a whole.

The focus is on a new treatment approach by a research team at Texas A&M University that aims to suppress inflammation in aging brains. The study reported that treatment administered nasally reduced brain inflammation in elderly mice and improved memory and cognitive function. ScienceDaily introduced this as "reversing brain aging with a simple nasal spray," garnering significant attention on international science news sites and social media.

However, it is important to emphasize that this is currently a preclinical study conducted on mice and has not been proven effective for human dementia patients. It is not akin to an over-the-counter nasal spray for hay fever. While the results are intriguing, it is too soon to conclude that "human brains will rejuvenate starting tomorrow."

The reason this research captures people's attention is clear. It reinterprets brain aging not as mere "wear and tear" but as an issue of controllable inflammation and energy dysfunction.

What Happens in an Aging Brain

When we think of brain aging, the image of neurons gradually decreasing and the shrinkage of memory-related areas is strong. However, in recent years, "neuroinflammation" has been highlighted as a significant feature of the aging brain.

With aging, mild inflammation can persist chronically in the brain, a condition known in English as "neuroinflammaging." Unlike acute inflammation that occurs during a cold or injury, it is akin to a low-grade fire smoldering in the brain.

Prolonged inflammation disrupts the function of the hippocampus, which is involved in memory and learning, and deteriorates the environment supporting neurons. Microglia, the brain's immune cells, also overreact, increasing inflammatory signals. Furthermore, mitochondria, the cell's energy factories, are burdened. Since the brain is an organ with high energy consumption, mitochondrial dysfunction can directly affect the quality of thought and memory.

This study aims to intervene in the vicious cycle of the aging brain by delivering treatment directly to the brain through the nose.

The Main Player in the Treatment: "Extracellular Vesicles"

At the core of this nasal spray are tiny particles called extracellular vesicles, or EVs. EVs are small "cargo capsules" released by cells that transport proteins and RNA to other cells.

The research team used EVs derived from neural stem cells created from human iPS cells. These EVs contain microRNAs that may regulate inflammation and gene expression in the brain. MicroRNAs are molecules that finely control the function of specific genes and signaling pathways, acting as "master regulators" of various biological processes.

Delivering drugs to the brain is one of the major challenges in medicine. The brain has a protective system called the blood-brain barrier, which prevents many substances from easily entering the brain from the bloodstream. While this is crucial for brain protection, it poses a barrier when trying to deliver medication.

This is where nasal administration comes into focus. Substances entering through the nose may reach the brain by bypassing the blood-brain barrier via pathways like the olfactory nerve. The research team emphasizes the "non-invasive access to the brain," making nasal administration an attractive option for future medical applications.

Changes Observed in Mouse Experiments

In the study, 18-month-old male and female mice were given EVs nasally twice. This age in mice corresponds to a stage where the effects of aging begin to appear, rather than being young adults. After administration, the research team examined hippocampal inflammation, oxidative stress, and memory-related behaviors at 20.5 months of age.

As a result, mice administered with EVs showed suppression of several inflammatory pathways. Particularly noteworthy were the NLRP3 inflammasome and the cGAS-STING pathway. Both are crucial signaling systems involved in aging, neuroinflammation, and immune response. When overactive, they can promote chronic inflammation and deteriorate the neuronal environment.

Additionally, indicators related to oxidative stress decreased, and improvements were observed in the genes and proteins supporting mitochondrial function. This suggests that not only was inflammation suppressed, but there may also have been positive effects on the brain cells' energy production system.

In behavioral tests, the EV-administered group showed improvements in tasks related to object recognition and spatial memory. Simply put, their ability to distinguish between familiar and new objects and notice environmental changes improved, indicating an enhancement in hippocampal-related memory function.

The ScienceDaily article also emphasized that the effects might have lasted for several months after just two administrations. If similar durability is confirmed in humans in the future, it could lead to treatment designs different from daily medication.

How Accurate is the Expression "Reversing Brain Aging"?

The key question is how much weight should be given to the expression "reversing brain aging."

The study demonstrated that in the hippocampus of aged mice, inflammation, oxidative stress, and mitochondrial-related abnormalities improved, and performance in memory tasks increased. This could indeed be described as "reversing" some of the brain function decline associated with aging.

However, human aging is far more complex. Cognitive decline involves many factors, including Alzheimer's pathology, vascular issues, sleep, lifestyle, genetics, social isolation, chronic diseases, and medication effects. Just because inflammation improved in the mouse hippocampus does not mean human dementia can be cured with a nasal spray.

Moreover, treatment using EVs involves numerous challenges to be addressed, such as manufacturing quality, safety, dosage, long-term effects, immune responses, and off-target effects. To use cell-derived microparticles as stable medical treatments, it is not enough to simply say "it worked"; it is necessary to clarify which components act on which pathways and how safely they can be used in which patients.

In other words, this research should be seen not as news of a completed nasal spray that can cure aging brains, but as a study suggesting that brain inflammation associated with aging might be a target for future intervention.

Why Does It Attract So Much Attention?

Nevertheless, it is natural for this research to attract significant attention. Dementia is a global issue, imposing a heavy burden not only on patients but also on families, caregivers, healthcare systems, and social security. In the U.S., the annual number of new dementia cases, which was about 514,000 in 2020, is projected to increase to about 1 million by 2060. In aging societies, preventing dementia, slowing its progression, and maintaining quality of life are becoming increasingly important.

Currently, drugs targeting amyloid-beta, a causative substance, have emerged for Alzheimer's disease. However, discussions continue regarding cost, side effects, administration methods, and the magnitude of effects. In this context, the idea of a treatment that can be administered nasally and acts on inflammation and cellular energy is appealing to many.

Particularly, the attempt to solve the challenge of "delivering drugs to the brain" through nasal administration and EVs is highly noteworthy in the research field. It is conceivable that it could be applied not only to dementia but also to recovery after stroke, traumatic brain injury, and chronic brain fog.

Expectations and Caution Spread Simultaneously on Social Media

On social media, there are three main reactions to this research.

The first is straightforward expectation. The headline "Nasal spray may reverse brain aging" has a very strong impact on the general public. For those who have experienced family dementia, suffer from forgetfulness or brain fog, or have concerns about an aging society, this news is easily received as hope.

The second is scientific caution. On LinkedIn, there were reactions showing interest in the fact that extracellular vesicles enter the central nervous system via nasal administration and suppress inflammation, with comments like "I want to see if it can be replicated." This is a typical reaction from those close to researchers or healthcare professionals. The more groundbreaking the results, the more important it is to see if the same results can be obtained in other laboratories or under different conditions.

The third is anxiety about practical application and skepticism about the system. In another LinkedIn post, comments were seen questioning why it hasn't been tested on humans yet, and concerns about the time and cost involved in clinical trials led by pharmaceutical companies. This is a common reaction in medical research news, where the greater the expectation, the stronger the impatience to "make it available soon."

On X, posts summarizing the research content were shared, including specialized keywords like NLRP3 inflammasome, cGAS-STING, and mitochondrial function. In Reddit's future technology community, article links were shared, indicating high interest in "technology to control aging."

However, caution is needed when reading reactions on social media. If only the headline spreads, it can easily lead to the misconception that "dementia can be cured with a nasal spray." At this point, the effects on humans are unconfirmed, and the focus of the research remains on mouse brain inflammation and memory tasks. While expectations on social media are natural, scientifically, it should be seen as standing at the entrance of a long verification process.

Steps Needed for Practical Application

Several stages must be overcome before this treatment can be used in humans.

First, safety confirmation is necessary. EVs are particles derived from living organisms and may affect multiple cells and pathways in the body. While suppressing brain inflammation itself is desirable, risks from excessively suppressing immune responses and long-term effects must also be investigated.

Next, there are issues of manufacturing and quality control. In EV treatment, it is crucial to determine from which cells they are made, how they are purified, and which components are considered active ingredients. Even if called the same EV, the contents and effects may change depending on manufacturing conditions. To be approved as a pharmaceutical, it must be possible to produce the same quality in large quantities consistently.

Furthermore, efficacy trials in humans are necessary. The trial design will vary completely depending on whether it is used in healthy elderly individuals, those with mild cognitive impairment, or Alzheimer's disease patients. It is also important to decide what to measure for effectiveness. Memory tests, brain imaging, inflammation markers, daily life functions, and long-term dementia incidence rates are evaluation indicators that must be carefully selected.

And the most challenging part is determining "who it works for." Even when simply referring to cognitive decline associated with aging, the causes differ among individuals. Some people have inflammation as the main cause, while others have significant vascular issues. In the future, it will be necessary to narrow down the treatment target by combining brain inflammation status, genetic background, lifestyle, existing diseases, and more.

There is Hope, but It Should Be a Calm Hope

The appeal of this research lies in showing the possibility that "an aging brain does not just deteriorate." By calming inflammation and regulating mitochondrial function, at least in mice, some memory functions can improve. This supports the view of brain aging as an intervenable biological process rather than a fixed fate.

On the other hand, excessive expectations are forbidden. In medical research, there are many cases where treatments successful in mice do not work the same way in humans. Dementia, in particular, is a complex condition involving human-like memory, language, daily functioning, personality, and sociality. The results of animal experiments cannot be directly translated into human treatment effects.

Nevertheless, this research cannot be ignored. It intersects multiple important themes, such as brain inflammation, EVs, nasal administration, and mitochondrial repair, which could significantly impact future neuroregenerative medicine and aging research.

The expectations that spread on social media, as well as the caution, are both correct. It is natural for people to feel hope in this news, and it is also natural for researchers to seek reproducibility and safety. The important thing is to watch the progress of science while holding both.

The phrase "rewinding brain aging with a nasal spray" is still in the future tense at this point. However, this research may have slightly illuminated a path toward that future.

Source URL

ScienceDaily. An article introducing the potential impact of nasal spray-type EV treatment on brain aging, memory, and brain fog based on a research announcement from Texas A&M University.
https://www.sciencedaily.com/releases/2026/05/260526022018.htm

Texas A&M University Official Story. A primary announcement explaining the research team's statements, treatment concept, potential of two administrations, and future prospects for cognitive therapy.
https://stories.tamu.edu/news/2026/04/14/scientists-reverse-brain-aging-with-a-nasal-spray/

Journal of Extracellular Vesicles Published Paper. An original paper reporting the impact of nasal administration of human iPS cell-derived neural stem cell EVs on inflammatory microglia transcription profiles, NLRP3, and cGAS-STING pathways in the hippocampus of aged mice.
https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70232

PubMed Listing Information. For checking bibliographic information and summaries of the original paper.
https://pubmed.ncbi.nlm.nih.gov/41656949/

NIH Research Matters. Used to confirm the projection that the number of new dementia cases in the U.S. will increase from about 514,000 in 2020 to about 1 million in 2060.
https://www.nih.gov/news-events/nih-research-matters/risk-future-burden-dementia-united-states

Neuroscience News. An article organizing the research content for the general public, explaining key points such as NLRP3, cGAS-STING, mitochondria, and cognitive function improvement.
https://neurosciencenews.com/nasal-spray-reverse-brain-aging-30519/

Example of Reaction on LinkedIn. A post by John Stockley showing interest in the point that EVs reach the central nervous system via nasal administration and suppress inflammation, with expectations for reproducibility confirmation.
https://www.linkedin.com/posts/john-stockley-6a992113_intranasal-human-nscderived-evs-therapy-activity-7465094190537015300-_ySv

Example of Reaction on LinkedIn. Comments on a post by Ashok K. Shetty